ZURICH, Oct 25 (Reuters) - Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk ...

And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...

In a Phase 3 trial of previously treated KRAS G12C-mutated non-small cell lung cancer, Roche’s investigational drug divarasib ...

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an ...

A new review details the major updates to the ACR's Lung-RADS system, from Category 0 and expanded juxtapleural criteria to ...

Nashville advocates say increasing lung cancer screening and awareness could catch the disease earlier, when patients have ...

Only 15% of eligible Americans get screened for lung cancer, translating to tens of thousands of preventable deaths every ...

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance ...

Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial ...

AstraZeneca (AZN) said Saturday two phase 3 trials showed its cancer drug Imfinzi helped patients with extensive-stage small cell lung cancer and muscle-invasive bladder cancer, cutting the risk of ...

The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing ...

Discover CHEST 2026 findings on CT phenotyping, TAPSE/sPAP risk scores, artesunate, telomere length and inhaled nintedanib in ...